Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

100%

6 of 6 completed trials have results

Key Signals

2 recruiting6 with results

Enrollment Performance

Analytics

Phase 3
4(50.0%)
Phase 2
4(50.0%)
8Total
Phase 3(4)
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT07457918Phase 3Recruiting

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

Role: lead

NCT07246590Phase 3Recruiting

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

Role: lead

NCT05188729Phase 2Completed

Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

Role: lead

NCT03487549Phase 2Completed

Cantharidin and Occlusion in Verruca Epithelium

Role: lead

NCT03981822Phase 2Completed

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

Role: lead

NCT03377790Phase 3Completed

Cantharidin Application in Molluscum Patients-1

Role: lead

NCT03377803Phase 3Completed

Cantharidin Application in Molluscum Patients

Role: lead

NCT03186378Phase 2Completed

Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.

Role: lead

All 8 trials loaded